Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
NEURO-ONCOLOGY (2013)
作者
我是这篇论文的作者
推荐
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial
Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta
NEURO-ONCOLOGY (2023)
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper
CLINICAL CANCER RESEARCH (2021)
A Review of Newly Diagnosed Glioblastoma
Bryan Oronsky, Tony R. Reid, Arnold Oronsky, Navjot Sandhu, Susan J. Knox
FRONTIERS IN ONCOLOGY (2021)
Interstitial photodynamic therapy for newly diagnosed glioblastoma
Stefanie Quach, Christoph Schwartz, Maximilian Aumiller, Marco Foglar, Michael Schmutzer, Sophie Katzendobler, Mohamed El Fahim, Robert Forbrig, Katja Bochmann, Rupert Egensperger, Ronald Sroka, Herbert Stepp, Adrian Ruehm, Niklas Thon
JOURNAL OF NEURO-ONCOLOGY (2023)
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma
Paul D. Brown, Caroline Chung, Diane D. Liu, Sarah McAvoy, David Grosshans, Karine Al Feghali, Anita Mahajan, Jing Li, Susan L. McGovern, Mary-Fran Mcaleer, Amol J. Ghia, Erik P. Sulman, Marta Penas-Prado, John F. de Groot, Amy B. Heimberger, Jihong Wang, Terri S. Armstrong, Mark R. Gilbert, Nandita Guha-Thakurta, Jeffrey S. Wefel
NEURO-ONCOLOGY (2021)
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)
Anne Laprie, Georges Noel, Leonor Chaltiel, Gilles Truc, Marie-Pierre Sunyach, Marie Charissoux, Nicolas Magne, Pierre Auberdiac, Julian Biau, Soleakhena Ken, Fatima Tensaouti, Jonathan Khalifa, Ingrid Sidibe, Franck-Emmanuel Roux, Laure Vieillevigne, Isabelle Catalaa, Sergio Boetto, Emmanuelle Uro-Coste, Stephane Supiot, Valerie Bernier, Thomas Filleron, Muriel Mounier, Muriel Poublanc, Pascale Olivier, Jean-Pierre Delord, Elizabeth Cohen-Jonathan-Moyal
NEURO-ONCOLOGY (2023)
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
AUTOPHAGY (2021)
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
NEURO-ONCOLOGY (2023)
Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial
Anuradha G. Trivedi, Karthik K. Ramesh, Vicki Huang, Eric A. Mellon, Peter B. Barker, Lawrence R. Kleinberg, Brent D. Weinberg, Hui-Kuo G. Shu, Hyunsuk Shim
CANCERS (2023)
Are We Ready for Migrastatics?
Jonathan Solomon, Magdalena Raskova, Daniel Rosel, Jan Brabek, Hava Gil-Henn
CELLS (2021)
Targeted therapies in patients with newly diagnosed glioblastoma-A systematic meta-analysis of randomized clinical trials
Angelika Scherm, Franziska Maria Ippen, Peter Hau, Hansjoerg Baurecht, Wolfgang Wick, Jens Gempt, Helge Knuettel, Michael F. Leitzmann, Corinna Seliger
INTERNATIONAL JOURNAL OF CANCER (2023)
Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy
Hire Hersi, Jukka Peltola, Jani Raitanen, Jukka T. Saarinen
FRONTIERS IN NEUROLOGY (2023)
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
Jeffrey S. Wefel, Terri S. Armstrong, Stephanie L. Pugh, Mark R. Gilbert, Merideth M. Wendland, David G. Brachman, Kevin S. Roof, Paul D. Brown, Ian R. Crocker, H. Ian Robins, Grant Hunter, Minhee Won, Minesh P. Mehta
NEURO-ONCOLOGY (2021)
Newly Diagnosed Glioblastoma in Elderly Patients
Carlen A. Yuen, Marissa Barbaro, Aya Haggiagi
CURRENT ONCOLOGY REPORTS (2022)
PARP inhibitors combined with radiotherapy: are we ready?
Chen Sun, Alan Chu, Rui Song, Shijia Liu, Ting Chai, Xin Wang, Zongwen Liu
FRONTIERS IN PHARMACOLOGY (2023)
Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma
Evanthia Galanis, Patrick Y. Wen, John F. de Groot, Michael Weller
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2022)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim, Michael Weller, Ahmed Idbaih, Joachim Steinbach, Gaetano Finocchiaro, Raju R. Raval, George Ansstas, Joachim Baehring, Jennie W. Taylor, Jerome Honnorat, Kevin Petrecca, Filip De Vos, Antje Wick, Ashley Sumrall, Solmaz Sahebjam, Ingo K. Mellinghoff, Masashi Kinoshita, Mustimbo Roberts, Ruta Slepetis, Deepti Warad, David Leung, Michelle Lee, David A. Reardon, Antonio Omuro
NEURO-ONCOLOGY (2022)
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
NEURO-ONCOLOGY (2023)
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
Philipp Karschnia, Jacob S. Young, Antonio Dono, Levin Haeni, Tommaso Sciortino, Francesco Bruno, Stephanie T. Juenger, Nico Teske, Ramin A. Morshed, Alexander F. Haddad, Yalan Zhang, Sophia Stoecklein, Michael Weller, Michael A. Vogelbaum, Juergen Beck, Nitin Tandon, Shawn Hervey-Jumper, Annette M. Molinaro, Roberta Ruda, Lorenzo Bello, Oliver Schnell, Yoshua Esquenazi, Maximilian Ruge, Stefan J. Grau, Mitchel S. Berger, Susan M. Chang, Martin van den Bent, Joerg-Christian Tonn
NEURO-ONCOLOGY (2023)
Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions
Marcel Buehler, Xiao Yi, Weigang Ge, Peter Blattmann, Elisabeth Rushing, Guido Reifenberger, Joerg Felsberg, Charles Yeh, Jacob E. Corn, Luca Regli, Junyi Zhang, Ann Cloos, Vidhya M. Ravi, Benedikt Wiestler, Dieter Henrik Heiland, Ruedi Aebersold, Michael Weller, Tiannan Guo, Tobias Weiss
NEURO-ONCOLOGY (2023)
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
NEURO-ONCOLOGY (2023)
Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study
Philipp Vollmuth, Martha Foltyn, Raymond Y. Huang, Norbert Galldiks, Jens Petersen, Fabian Isensee, Martin J. van den Bent, Frederik Barkhof, Ji Eun Park, Yae Won Park, Sung Soo Ahn, Gianluca Brugnara, Hagen Meredig, Rajan Jain, Marion Smits, Whitney B. Pope, Klaus Maier-Hein, Michael Weller, Patrick Y. Wen, Wolfgang Wick, Martin Bendszus
NEURO-ONCOLOGY (2023)
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurel Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Froehlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Gruener, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K. H. van Landeghem, Torsten Pietsch, Jorg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Bruestle, Matthias Simon, Martin Glas, Bjoern Scheffler
CLINICAL CANCER RESEARCH (2023)
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
EUROPEAN JOURNAL OF CANCER (2023)
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. Mellinghoff, L. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen
NEURO-ONCOLOGY (2023)
Stroke-associated infections in patients with and without cancer
Katharina Seystahl, Juliane Schweizer, Mira Katan, Sung Ju Weber, Alessia Hug, Miriam Wanner, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
NEURO-ONCOLOGY PRACTICE (2023)
Immunotherapy for brain metastases and primary brain tumors
Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio
EUROPEAN JOURNAL OF CANCER (2023)
Association of antidepressant drug use with outcome of patients with glioblastoma
Corinna Seliger, Felix Boakye Oppong, Florence Lefranc, Olivier Chinot, Roger Stupp, Burt Nabors, Thierry Gorlia, Michael Weller, EORTC Brain Tumor Group
INTERNATIONAL JOURNAL OF CANCER (2023)
Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma models
Evelina Blomberg, Manuela Silginer, Patrick Roth, Michael Weller
TRANSLATIONAL ONCOLOGY (2023)
A risk model for prediction of diagnosis of cancer after ischemic stroke
Katharina Seystahl, Dorothee Gramatzki, Miriam Wanner, Sung Ju Weber, Alessia Hug, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
SCIENTIFIC REPORTS (2023)